Jun 22, 2020
Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis
May 18, 2020
Oculis Reports Positive Top-line Data From SKYGGN (Phase 2) Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery
Feb 25, 2020
Uveitis Treatment Market Worth $687.4 Mn, by 2026 at 4.6% CAGR: Allied Market Research
Nov 26, 2019
Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis Published in Therapeutic Advances in Respiratory Disease
Nov 19, 2019
Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agency
Oct 23, 2019
Bausch Health Licenses Clearside Biomedical's XIPERE(TM) (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis
Sep 18, 2019
Anterior Uveitis Treatment Market Size Worth $418.23 Million By 2026: Grand View Research, Inc.
Sep 16, 2019
Tarsius Pharma Awarded EUR2.4 Million EU Grant to Support First-in-human Clinical Trial for TRS01
Jul 11, 2019
The United States Uveitis Market to 2024: Pipeline; Epidemiology; Market Valuations; Drugs, Sales, and Market Share
Apr 30, 2019
Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial
Apr 29, 2019
The ACR and the Arthritis Foundation Present New Guidelines Offering Therapeutic Approaches and Treatment Options for Juvenile Idiopathic Arthritis
Apr 09, 2019
Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics
Feb 28, 2019
Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day
Feb 12, 2019
Aldeyra Therapeutics to Host 2019 Research & Development Day
Nov 02, 2018
Global Uveitis Market and Competitive Landscape Report 2018-2023 - Develop Tactics and Strategies to Take Advantage of Opportunities in the Market
Oct 26, 2018
First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Aug 09, 2018
Eyevensys Appoints New Board Member, Gerald Cagle
Mar 29, 2018
Aldeyra Therapeutics Announces Year End 2017 Financial Results
Mar 15, 2018
Asia-Pacific Uveitis Therapeutics Markets to 2023 - Market will be Valued at $405.5m
Jan 30, 2018
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial